Alkermes reports ALKS 7290 ADHD trial data
Alkermes (NASDAQ:ALKS) reported positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, an investigational orexin 2 receptor agonist being developed for attention-deficit hyperactivity disorder (ADHD).











